News & Events about Cara Therapeutics Inc.
Ticker Report
4 months ago
Cara Therapeutics, Inc. (NASDAQ:CARA Get Rating) Director Martin Vogelbaum sold 10,800 shares of Cara Therapeutics stock in a transaction that occurred on Wednesday, September 14th. The stock was sold at an average price of $10.28, for a total value of $111,024.00. Following the transaction...
Globe Newswire
5 months ago
Kapruvia (difelikefalin) is the first and only therapy approved through consortium filing for the treatment of chronic kidney disease (CKD)-associated pruritus in hemodialysis patients Therapy recently approved in Canada under the brand name KORSUVA Regulatory decisions in Australia and Singapore ...
Globe Newswire
9 months ago
First approved therapy in Europe for the treatment of chronic kidney disease (CKD)-associated pruritus in hemodialysis patientsFirst launches in Europe expected in H2 2022 ST. GALLEN, Switzerland and STAMFORD, Conn., April 28, 2022 (GLOBE NEWSWIRE) -- Vifor Fresenius Medical Care Renal Pharma (...
Ticker Report
9 months ago
Oppenheimer Co. Inc. lessened its stake in shares of Cara Therapeutics, Inc. (NASDAQ:CARA Get Rating) by 28.9% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 13,555 shares of the biopharmaceutical ...
Oppenheimer & Co. Inc. reduced its position in shares of Cara Therapeutics, Inc. (NASDAQ:CARA Get Rating) by 28.9% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 13,555 shares of the biopharmaceutical companys stock after selling 5,500 shares during the period. ...